Tegobuvir

DB11852InvestigationalSmall molecule

Tegobuvir has been investigated for the treatment of Hepatitis C, Chronic.

Mechanism: Pharmacologically active on RNA-directed RNA polymerase
Curator reviewed
Formula / weight: C₂₅H₁₄F₇N₅ · 517.411 g/mol (avg)
Code names: GS-9190

Resolves to

Compound

Structure

InChIKeyXBEQSQDCBSKCHJ-UHFFFAOYSA-NSMILESFC1=CC=CC=C1C1=NC2=CN(CC3=CC=C(N=N3)C3=CC=C(C=C3C(F)(F)F)C(F)(F)F)C=CC2=N1

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tegobuvir, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.